Skip to main content

Table 2 Response of patients with measurable disease

From: Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study

Response

All

RAS mutant

RAS WT

BRAFV600E mutant

RAS/BRAFV600E WT

n = 48

n = 18

n = 24

n = 8

n = 16

PR

34(70.8%)

13 (72.2%)

19 (79.2%)

4 (50.0%)

15 (93.8%)

SD

9 (18.8%)

4 (22.2%)

3 (12.5%)

2 (25.0%)

1(6.3%)

PD

4(8.3%)

1 (5.6%)

2 (8.3%)

2 (25.0%)

0

NE

1 (2.1%)

0

0

0

0

NED

1(2.1%)

0

0

0

0

ORR

70.8%

72.2%

79.2%

50.0%

93.8%

DCR

89.6%

94.4%

91.7%

75.0%

100%

  1. Genotype and response rate, Fisher exact probability test (two-sided), BRAF V600E mutant vs. RAS/BRAFV600E WT, p = 0.028
  2. DCR Disease control rate, NED No evidence of disease, ORR Objective response rate, PR Partial response, SD Stable disease, WT wild-type